RYGB and the Gastric Adipose Axis
Completed · Phase 1
Conditions studied: Obesity
In brief
The purpose of this study is to determine if interruption in gastric-adipose tissue axis signaling contributes to early improvements in oxidative stress, insulin sensitivity, and inflammation, and to determine if interruption of the stomach in RYGB results in reduction of plasma acylated ghrelin (AG) and in an altered acylated ghrelin:unacylated ghrelin (AG:UAG) ratio which may contribute to decreased oxidative stress and improved insulin sensitivity.
Key facts
- Study ID
- NCT01474785
- Run by
- Vanderbilt University
- People needed
- 49
- Starts
- 2012-01-01
- Expected to finish
- 2015-07-01
- Last updated by the study team
- 2018-05-21
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-65 years
- BMI ≥ 35 kg/m\^2
- Scheduled for bariatric surgery
- Considering bariatric surgery
- Waiting for insurance approval for bariatric surgery
- Currently not considering bariatric surgery, but otherwise eligible
- Enrollment in medical weight loss program
You may not qualify if…
- Smoking >7 cigarettes per day
- Precious malabsorptive or restrictive intestinal surgery
- Pregnant or breastfeeding
- Recent history of neoplasia (5<years ago)
- Malabsorptive syndromes
- Inflammatory intestinal disease
- Established organ disfunction
- Allergy to acetaminophen
Where it is running
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.